Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00

Keros Therapeutics (NASDAQ:KROS) had its target price reduced by Wells Fargo & Company from $23.00 to $20.00 in a research report report published on Thursday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Several other research firms have also issued reports on KROS. Oppenheimer reissued an “outperform” rating and set a $27.00 target price (up from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. Wedbush boosted their price target on shares of Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Zacks Research lowered shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Bank of America raised their price objective on shares of Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a research note on Friday, November 28th. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Keros Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $21.86.

Keros Therapeutics Stock Down 3.5%

NASDAQ:KROS opened at $11.30 on Thursday. The stock’s fifty day moving average is $17.41 and its two-hundred day moving average is $17.05. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $22.55. The stock has a market capitalization of $344.31 million, a price-to-earnings ratio of 6.21 and a beta of 0.87.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.37). Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.The firm had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $3.66 million. During the same quarter in the prior year, the business earned ($1.14) earnings per share. The company’s quarterly revenue was down 87.2% on a year-over-year basis. On average, sell-side analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its holdings in Keros Therapeutics by 8.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares during the period. UBS Group AG boosted its stake in shares of Keros Therapeutics by 1.1% in the 3rd quarter. UBS Group AG now owns 103,864 shares of the company’s stock valued at $1,643,000 after buying an additional 1,091 shares during the period. Strs Ohio boosted its stake in shares of Keros Therapeutics by 3.9% in the 4th quarter. Strs Ohio now owns 29,300 shares of the company’s stock valued at $597,000 after buying an additional 1,100 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after buying an additional 1,166 shares in the last quarter. Finally, Financial Management Professionals Inc. acquired a new position in shares of Keros Therapeutics during the fourth quarter worth about $29,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Keros Therapeutics

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: Pipeline progress — Keros is advancing rinvatercept for Duchenne muscular dystrophy, has FDA orphan drug designation, and plans a Phase II trial in 2026; this development supports long‑term upside if clinical data are supportive. Read More.
• Positive Sentiment: Mixed near‑term earnings view improved slightly for FY2026 — HC Wainwright raised its FY2026 EPS loss forecast (less negative) to ($3.66) from ($4.01), which could temper downside if cash‑burn or operational outlook follows a similar trend. Read More.
• Neutral Sentiment: Smaller reporting status announced — Keros’ change to smaller reporting status reduces disclosure burden but may reduce investor appeal and trading interest, a mixed factor for liquidity and volatility. Read More.
• Negative Sentiment: Broad EPS downgrades from HC Wainwright — The firm cut Q1–Q4 2026 quarterly EPS forecasts (now ~($0.89)–($0.93) per quarter) and materially lowered FY2027–FY2029 estimates, signaling weaker near‑ and mid‑term profitability expectations. These reductions are a primary driver of downward pressure on the stock. Read More.
• Negative Sentiment: Sell rating issued — Wall Street Zen/analyst downgrade to a Sell adds immediate negative sentiment and likely contributed to today’s price decline. Read More.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.